Pramipexole in the treatment of Parkinson’s disease: new developments

References

• Oertel WH, Fahn S. Parkinsonism. In: Neurological disorders: course and treatment. Brandt T, Diener HC, Caplan LR (Ed.). Academic Press, San Diego, 1021–1079 (2003).
   Google Scholar
• Hubble JP, Novak P. Pramipexole: a nonergot dopamine agonist as drug therapy in Parkinson’s disease. Expert Rev. Neurotherapeutics 1, 43–51 (2001).
   PubMedGoogle Scholar
• Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neurone firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur. J. Pharmacol. 312(1), 35–44 (1996).
   PubMed Web of Science ®Google Scholar
• Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur. J. Pharmacol. 215, 161–170 (1992).
   PubMed Web of Science ®Google Scholar
• Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J. Clin. Pharmacol. 37(6), 520–525 (1997).
   PubMed Web of Science ®Google Scholar
• Kompoliti K, Adler CH, Raman R et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 58(9), 1418–1422 (2002).
   PubMed Web of Science ®Google Scholar
• Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study Group. Neurology 49(4), 1060–1065 (1997).
   PubMed Web of Science ®Google Scholar
• Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49(1), 162–168 (1997).
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Yanagisawa N, Kuno S et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov. Disord. 18, 1149–1156 (2003).
   PubMed Web of Science ®Google Scholar
• Möller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov. Disord. 20(5), 602–610 (2005).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson’s disease. JAMA 284(15), 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs. levodopa as initial treatment for Parkinson’s disease: a 4-year randomized controlled trial. Arch. Neurol. 61(7), 1044–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Marras C, Lang A, Krahn M, Tomlinson G, Naglie G. Quality of life in early Parkinson’s disease: impact of dyskinesias and motor fluctuations. Mov. Disord. 19(1), 22–28 (2004).
   PubMed Web of Science ®Google Scholar
• Noyes K, Dick AW, Holloway RG. Pramipexole vs. levodopa as initial treatment for Parkinson’s disease: a randomized clinical–economic trial. Med. Decis. Making 24(5), 472–485 (2004).
   PubMed Web of Science ®Google Scholar
• Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91, 1075–1081 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson’s disease progression. JAMA 287(13), 1653–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 56(11), 1559–1564 (2001).
   PubMed Web of Science ®Google Scholar
• Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 11(2), 58–65 (2000).
   PubMed Web of Science ®Google Scholar
• Wermuth L. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson’s disease. Eur. J. Neurol. 5(3), 235–242 (1998).
   PubMed Web of Science ®Google Scholar
• Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur. J. Neurol. 10(4), 399–406 (2003).
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J. Neuropsychiatry Clin. Neurosci. 17(2), 214–220 (2005).
   Google Scholar
• Künig G, Pogarell O, Möller JC, Delf M, Oertel WH. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson’s disease. Clin. Neuropharmacol. 22(5), 301–305 (1999).
   PubMedGoogle Scholar
• Pogarell O, Gasser T, van Hilten JJ et al. Pramipexole in patients with Parkinson’s disease and marked drug-resistant tremor: a randomised, double-blind, placebo-controlled multicentre study. J. Neurol. Neurosurg. Psychiatry 72(6), 713–720 (2002).
   PubMed Web of Science ®Google Scholar
• Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. Mov. Disord. 18(11), 1324–1331 (2003).
   PubMedGoogle Scholar
• Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson’s disease is associated with cardiac valve regurgitation. Neurology 63(2), 301–304 (2004).
   PubMed Web of Science ®Google Scholar
• Van Camp G, Flamez A, Cosyns B et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363, 1179–1183 (2004).
   PubMed Web of Science ®Google Scholar
• Grosset K, Needleman F, Macphee G, Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: a clinical series and five-drug dose conversion table. Mov. Disord. 19(11), 1370–1374 (2004).
   PubMed Web of Science ®Google Scholar
• Linazasoro G. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson’s disease. J. Neurol. 251(3), 335–339 (2004).
   PubMed Web of Science ®Google Scholar
• Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52(9), 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson’s disease: a survey by the Canadian Movement Disorders Group. JAMA 287(4), 455–463 (2002).
   PubMed Web of Science ®Google Scholar
• Körner Y, Meindorfner C, Möller JC et al. Predictors of sudden onset of sleep. Mov. Disord. 19, 1298–1305 (2004).
   PubMed Web of Science ®Google Scholar